Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
abemaciclib, agreed, Alvogen, automated, BARDA, binding, BLA, breast, Buyer, CDK, conjugate, criteria, customary, discern, disposal, disposition, divest, divestiture, earnout, Eli, England, Erwinaze, exposure, expression, featuring, fourth, Genovac, group, HitGen, Hong, IgA, immunized, immunogenicity, India, Jazz, Johnson, Kong, licensure, Lilly, mainland, meaningfully, metastatic, multicenter, myasthenia, NaN, nephropathy, nerve, nontransferable, OmniTaur, personnel, Pfenex, pneumococcal, proposed, PROTECT, removing, resolution, resolved, retention, robust, scope, Seller, Serum, solved, submission, subsidary, Subtopic, sugemalimab, tied, timeframe, Ultralong, vaccine, voluntary, xCella
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view